In 1991,246 and 136 OntarIo laboratories performed total creatine kinase (CK; EC 2.7.3.2) and creatine kinase-2 (CK-2) assays, respectively. A questionnaire mailed to these laboratories requested information about the types of assay used, the origin of their reference ranges, and the source of their instruments and reagents. All laboratones used current test formulations for CK, afthough seven laboratories did not assay at 37#{176}C. For CK, 69% of all laboratories reported different upper reference limits for men and women (5th-95th percentiles: 160-250 and 115-215 U/L, respectively); 31% reported similar ranges for both sexes. Fifty-six percent derived their own ranges; the remainder used either kit inserts or literature references, and nearly 60% of this latter group claimed to have validated these suggested ranges before use. For 6% of all laboratories, their pediatric ranges were similar to their adult ranges. For CK-2, only 32% used their own reference range; the remainder used kit inserts or literature laboratories were asked to provide their upper reference ranges for both total CK and CK-2 in men (2), the Enzyme and Lipids Committee noticed a wide range of reported values for these analytes. In addition, our experience of on-site inspections of laboratories having an unsatisfactory performance in proficiency testing suggested that laboratory staff, even senior staff, were not always fully cognir.ant of the details of a particular assay system. Given that the current formulation of the CK assay is particularly complex (3), we believed that inquiry into the principles of that assay might also be of value. Therefore, we issued questionnaires to all laboratories licensed to perform total CK and CK.2 assays, to obtain further information about these assays with regard to #{149} the methods in use and the level of laboratorians' understanding of the principles on which the methods are based #{149} the ranges used for male, female, and pediatric populations, and #{149} the way in which these ranges were obtained (4), i.e., by the laboratory's own determinations, by the manufacturers analytical method (package insert), or by methods found in the literature; if the latter two sources were used, did the laboratory validate these derived ranges locally?
whether owned by hospitals or commercial enterprises, and providing educational assistance to all such laboratories. Testing is assigned to 14 working committees, one of which is the Enzyme and Lipids Committee.
During surveys assessing performance of determinations of creatine kinnae (CK; EC 2.7.3.2) isoenzyme 2 (CK-2, or CK-MB), in which all participating laboratories were asked to provide their upper reference ranges for both total CK and CK-2 in men (2) , the Enzyme and Lipids Committee noticed a wide range of reported values for these analytes. In addition, our experience of on-site inspections of laboratories having an unsatisfactory performance in proficiency testing suggested that laboratory staff, even senior staff, were not always fully cognir.ant of the details of a particular assay system. Given that the current formulation of the CK assay is particularly complex (3), we believed that inquiry into the principles of that assay might also be of value. Therefore, we issued questionnaires to all laboratories licensed to perform total CK and CK.2 assays, to obtain further information about these assays with regard to #{149} the methods in use and the level of laboratorians' understanding of the principles on which the methods are based #{149} the ranges used for male, female, and pediatric populations, and #{149} the way in which these ranges were obtained (4), i.e., by the laboratory's own determinations, by the manufacturers analytical method (package insert), or by methods found in the literature; if the latter two sources were used, did the laboratory validate these derived ranges locally?
The health-care system of Ontario serves a population of 9.5 million people (-36% of Canada's population), similar to the population size of Michigan (9.2 million) or Ohio (10.8 million); therefore, the results of this survey are likely to be of interest to other North American health-care organizations.
To our knowledge, this is the first such survey of an entire health-care system under a single administrative organization.
Materials and Methods

LaboratOrieL
The 246 and 136 Ontario laboratories licensed, respectively, to determine total CK and CK-2 were surveyed by an LPTP postal inquiry to each laboratory director in April 1991.
CK questionnaire. The LPTP Committee asked for the assay temperature, thiol activator(s), adenylate kinase inhibitor(s) used in the assay, and the manufacturer's method insert. 
Results
Total CK Assay
Of the 246 laboratories, 97% used an assay temperature of 37#{176}C; the remaining 7 laboratories used 30#{176}C. The characteristics of the total CK assays are listed in Table 1 .
The major analyzer types, used at 37#{176}C, are described in Table 2 . Eight analyzer types accounted for 79% of the analyzers used in the Province for total CK analyses. Figure 1 shows the upper reference limit for men by analyzer type. We also classified upper limits for men by some locations (Figure 2 ). Data obtained from Hamilton ( Figure 2C) Table 2 ) and an Olympus AU5031 analyzer. Upper reference limits (37 #{176}C). Of the 239 laboratories, 74 (31%) had the same reference ranges for both men and women (a further 6% did not report any reference value for women at all): the 5th-95th percentiles were 130-253 UIL (median 206 U/L). Of the 239 laboratories, 41 (17.2%) used their own reference range, 36 used the manufacturer's kit insert range, and 4 used a range from a literature source; 7 of these laboratories used more than one source for their reference ranges.
Of the remaining 165 laboratories (69%), 93 (38.9%) used their own reference range, 72 used the manufacturer's kit insert range, and 8 used a range from a literature source. Twelve laboratories used more than one source for these ranges. Of the 68 laboratories using a manufacturer's or literature reference range, 48 (70.6% of 68 laboratories) claimed to have validated the ranges they were using. When the ranges for each sex were dissimilar, the following 5th-95th percentiles (and median values) were reported for the total CK assays 
CK-2 Assay
The types of assay used by the 136 laboratories to detect CK-2 are shown in Responses were sufficient to display mass assay ranges for only the Abbott IMx ( Figure SE) .
The methods of reporting CK-2 results are listed in Table 4 . Most laboratories used both activity (or mass) and CK-2 fraction of total CK activity (or relative index). Table 3 ). than 3% of all respondents omitted mention of the presence of thiol agents in both assays. That these lacunae in understanding were not unique was underscored by the previously mentioned failure to recognize that male, female, and pediatric reference ranges differ and that a single, sex-neutral range is unacceptable.
Dlscuulon
Understanding of the Principles of the
Total
CK
Nearly all laboratories used the currently recommended formulation for the total CK assay (7) . (10) from a population of --8OO0 men and women. Although there can be no "gold standard" for such values, the essential reliability of the majority of the Ontario data appears to be confirmed by the agreement with these very extensive US data. However, the validity of values >250 and <160 U/L reported by 20 laboratories for the upper reference limit for men, and >215 and <115 UIL reported by? laboratories for the upper reference limit for women, when using an optimized assay at 37#{176}C, must be questioned.
Likewise, despite the significant difference between total CK values in men and women (9-14), 37% of Ontario laboratories licensed to perform total CK assays did not recognize this difference. Finally, we seriously question the validity of the very wide scatter of the reported Considerable racial heterogeneity exists in populations, and these racial differences profoundly affect total CK values (11) (12) (13) --to the extent that different racial reference limits have been suggested (12). In general, such heterogeneity should broaden the reported ranges, but in the 56% of Ontario laboratories that actually derived their own reference ranges, such an explanation seems unlikely, because several of these laboratories reported rather low values.
Almost all of the plots in Figure 1 show, for the majority of users, a central plateau or a series of plateaus with a mid-point near 200 UIL. This is also the median value of the data obtained for men, which agrees with the extensive US data mentioned above. In other words, the central tendency for each instrument and reagent combination is consistent from instrument to instrument.
However, as already mentioned, some ranges for men extend to extreme values. How did these arise? Some values obtained by the laboratory were stated to have been deliberately set low, e.g., in the range 80-130 U/L, to rule out myocardial infarction (this point will be discussed later). Other values, in the same range, were claimed to have been taken from the kit insert, but the accompanying insert did not support these claims and no effort had been made to validate such values locally. Of the 11 values >250 UIL, two were borderline (253 U/L) and the remainder were claimed to be based on kit insert values, only some of which could be verified by the LFI'P Committee from the attached inserts. The majority of the "rogue" values seen in the plots by location (Figure 2) derive from those already mentioned; we assume that future efforts to standardize reference ranges within a community will remove these anomalies.
The differences between different laboratories in the same location are of considerable concern. For example, in one community, a total CK activity of 220 U/L is abnormal in three laboratories but normal in another three. (A similar set of circumstances was found for the seven laboratories reporting anomalous ranges for women-these will therefore not be discussed further.)
We also asked for details of the process by which laboratories obtained their own reference ranges. Several reported that their records were missing, or staff had changed, so that details could not be provided other than the actual ranges themselves.
Record keeping of such data obviously from 15 in a small community hospital to 1490 in bigger commercial and hospital laboratories, where data from several hospitals had been pooled. The population used usually included outpatients, staff, some inpatients, or groups of subjects undergoing insurance examinntions. Many laboratories attempted to have equal numbers of male and female subjects, but others did not state their sex ratio. One community hospital mentioned that, because many of their subjects performed heavy manual labor, they had to adjust the resulting reference range downwards to be more representative of the general population this was one of the few laboratories to appreciate the effect of exercise on the CK values (15) . One laboratory enclosed a copy of their preanalytical protocol for deriving a reference range: volunteers were asked about their state of health;
the time of last meal and fluid intakes; any medication use, including aspirin, sedatives, tranquilizers, or birth control drugs; and the performance of vigorous exercise within the last 48 h. A small laboratory, with a correspondingly small operating budget, commented on the expense of deriving a reference range (because they were using an expensive immunoassay). Several respondents mentioned that obtaining a reference range was beyond their capabilities: they were already understaffed and simply did not have the time. Many laboratories, both hospital-based and commercial, pooled data and resources to obtain a more useful estimation of CK ranges in a locale (see, e.g., Figure 2C ). The most commonly cited literature reference used by laboratories as a source for their reference range was Tietz (16).
Many of the responses to the questionnaire indicated that a major use of the total CK reference limit is to rule in, or out, myocardial infarction-although this use demonstrates a naive understanding of the entire process. Such a process actually requires the careful prior selection of subjects (17) , a process that is not usually performed and one that produces decision thresholds that may differ widely from the conventionally derived upper reference limit. For example, whereas a conventionally derived upper reference limit for men (based on results for >200 healthy hospital stafi) was 174 U/L, the decision thresholds for ruling in myocardial infarction were 250,400, and 800 U/L for test specificities of 90%, 95%, and 99%, respectively, when an appropriately matched nondiseased population was used (18). By contrast, the decision thresholds for ruling out myocardial infarction, for test sensitivities of 90%, 95%, and 99%, were 40,30, and 20 U/L, respectively, 6 h after the onset of chest pain (18). Table 3 shows the present distribution of CK-2 methods in the Province, 82% of which are activity-based assays. The data in Table 3 should be compared with recent US evidence, i.e., a survey of the College of American Pathologists (19) in which 62% of the participants used mass assays, whereas immunoinhibition, electrophoresis, and ion-exchange (DuPont) assays each accounted for <15% of participants.
CK-2
The CK-2 upper reference limits are shown in Figure  3 for selected methods: there appear to be grounds for a review of some of these upper reference limits or for considering a change in methodology.
When the 5th-95th percentiles are taken into account (see Results section), the mass assays clearly demonstrate a much tighter distribution. These Ontario data are reflected in pilot studies conducted by this LPTP Committee and also in the results of the survey already referred to (19).
About half of those laboratories that used kit insert or literature CK-2 reference values validated them by er1nhining diagnostic records in consultation with clinical staff. However, such a process could introduce a selection bias, which might explain some of the extremely high activities in Figure 3 (A and C) .
To our knowledge, this is the first survey of the reference ranges in use in a single health-care administrative unit, involving nearly 10 million people. Our findings are not reassuring. As a result of this survey, the LPTP Enzyme and Lipids Committee has formulated, and has proceeded to implement, the following objectives:
derivation of acceptable CK reference ranges by any laboratory that (a) has ranges falling outside the 5th-95th percentiles (men: 160-250 U/L, women: 115-215 U/L) established by this survey or (b) does not have appropriate differences between men, women, and pediatric reference ranges (as a corollary, we wish to encour-1370 CLINICAL CHEMISTRY, Vol. 38, No. 7, 1992 age those laboratories that derived their ranges from kit inserts or literature references to validate these ranges within a local setting).
#{149} standardization of CK reference ranges within a community.
#{149} exploration of educational initiatives for improving knowledge of the essential elements of a satisfactory CK assay.
